Business
Voyageur Secures $687k of Additional Capital from Warrant Exercises
(TheNewswire) Voyageur streamlines capitalization table through exercise of 5,7...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Secures $687k of Additional Capital from Warrant Exercises\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Voyageur streamlines capitalization\ntable through exercise of 5,725,829 warrants, expiry of 8,844,935\nwarrants\n \n\n\n\n\n\n Strong existing shareholder support,\nraising gross proceeds of $687,099\n \n\n\n\n\n\n Calgary, Alberta, Canada – January 23, 2025 –\n \n\n TheNewswire -\n \n\n Voyageur\nPharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“\n \n\n Voyageur\n \n\n ” or the\n“\n \n\n Company\n \n\n ”), a company planning to vertically integrate the medical\nimaging industry, is pleased to announce that it has received\nsignificant investor support, as effective January 20, 2025, the\nCompany received aggregate gross proceeds of $687,099 through the\nexercise of 5,725,829 share purchase warrants (“\n \n\n Warrants\n \n\n ”),\nresulting in the issuance of  an aggregate of 5,725,829 common shares\nof the Company (“\n \n\n Common\nShares\n \n\n ”). The Warrants were issued pursuant to\na second closing of a private placement of units of the Company that\nclosed on January 20, 2023, pursuant to which an aggregate of\n14,570,764 Warrants were issued. Following the exercises, 8,844,935\nWarrants expired unexercised. In addition, in December 2024, an\nadditional 2,571,369 Warrants expired unexercised, further\nstreamlining the capitalization table.\n \n\n\n\n Brent Willis, Voyageur’s President, CEO and Director,\nexpressed, “We sincerely appreciate the support our existing\ninvestors have placed in us. The warrant exercises will give Voyageur\nadded flexibility in achieving its goals to become a leader in the\nradiology drug market”.\n \n\n\n\n Voyageur achieved significant milestones in 2024 and\nmanagement believes it is poised for further success in 2025. The\nCompany strengthened partnerships, introduced innovative products, and\nexpanded leadership roles to drive growth. Voyageur completed a CAD\n$2.7 million sales contract\n \n\n\n\n on May 28,\n2024\n \n\n\n\n , entered into a Letter of Intent\nwith a major multinational company on\n \n\n\n\n December 20,\n2024\n \n\n\n\n , and is preparing to launch five\nHealth Canada licensed barium contrast products into market t...